Nicholas Vogelzang
Nearby
Get Featured on Wellness.com
> Learn More
Oncologists
Comprehensive Cancer Centers of Nevada
Las Vegas, NV
Comprehensive Cancer Centers of Nevada
Las Vegas, NV
Comprehensive Cancer Centers of Nevada
LAS VEGAS, NV
Comprehensive Cancer Centers of Nevada
Las Vegas, NV
Nicholas J. Vogelzang, MD, FASCO, FACP
3730 S Eastern Avenue
Las Vegas, NV 89169
About
Prior to joining Comprehensive, he served as Director of Nevada Cancer Institute from 2004 to 2009. From 1999 to 2003, Dr. Vogelzang was Fred C. Buffett Professor and Director of the University of Chicago Cancer Research Center and faculty member from 1982 to 2003.
Dr. Vogelzang leads and participates in multiple clinical trials in genitourinary malignancies, phase1 and mesothelioma focusing on new therapies for patients with metastatic kidney, bladder and prostate cancer. He has lead research in Las Vegas for two FDA-approved prostate cancer treatments – Provenge and Xofigo. In 2014, Nature published the international phase 1 teams research on an anti-PD-L1 treatment called atezolizumab (commercially known as TECENTRIQ) for metastatic bladder cancer. The FDA approved the treatment in May 2016.
Dr. Vogelzang was named Distinguished Physician of the year by the Nevada State Medical Association and received the Laureate award from the American College of Physicians in Nevada in 2013. He has been named America’s Top Doctor by Castle Connolly, Top Doctor by U.S. News & World Report, Best Physicians in Southern Nevada as chosen by their peers by Desert Companion, Everyday Hero from the American Red Cross Southern Nevada, Health Care Headliner by Vegas Inc. and Medical Marvels by Nevada Business Magazine. He was also awarded the Gold Certificate of Excellence by National Cancer Institute and the Inspired Excellence in Health Care Award by Las Vegas HEALS.
Dr. Vogelzang has been featured in several national and local media outlets in relation to his cancer research work including The New York Times, USA Today, New England Journal of Medicine, Nature, 60 Minutes and the Las Vegas Review-Journal.
Dr. Vogelzang has served on numerous committees for the American Society of Clinical Oncology (ASCO), as well as on its board of directors for three years.
Nicholas Vogelzang
Dr. Vogelzang is a renowned medical oncologist and cancer researcher who has authored/coauthored numerous peer-reviewed articles, book chapters and abstracts. He was the lead editor of the Comprehensive Textbook of Genitourinary Oncology from 1994-2008. Dr. Vogelzang joined Comprehensive Cancer Centers as a medical oncologist in 2009. He serves as the Associate chair of the Genitourinary (GU) Committee for US Oncology Research and Vice Chair of GU Committee SWOG, a worldwide network of researchers that design and conduct cancer clinical trials. Dr. Vogelzang serves as Clinical Professor of Medicine at University of Nevada School of Medicine as well as Clinical Professor at UNLV School of Medicine. He is also Associate Editor of Kidney Cancer Journal and Clinical Genitourinary Cancer.Prior to joining Comprehensive, he served as Director of Nevada Cancer Institute from 2004 to 2009. From 1999 to 2003, Dr. Vogelzang was Fred C. Buffett Professor and Director of the University of Chicago Cancer Research Center and faculty member from 1982 to 2003.
Dr. Vogelzang leads and participates in multiple clinical trials in genitourinary malignancies, phase1 and mesothelioma focusing on new therapies for patients with metastatic kidney, bladder and prostate cancer. He has lead research in Las Vegas for two FDA-approved prostate cancer treatments – Provenge and Xofigo. In 2014, Nature published the international phase 1 teams research on an anti-PD-L1 treatment called atezolizumab (commercially known as TECENTRIQ) for metastatic bladder cancer. The FDA approved the treatment in May 2016.
Dr. Vogelzang was named Distinguished Physician of the year by the Nevada State Medical Association and received the Laureate award from the American College of Physicians in Nevada in 2013. He has been named America’s Top Doctor by Castle Connolly, Top Doctor by U.S. News & World Report, Best Physicians in Southern Nevada as chosen by their peers by Desert Companion, Everyday Hero from the American Red Cross Southern Nevada, Health Care Headliner by Vegas Inc. and Medical Marvels by Nevada Business Magazine. He was also awarded the Gold Certificate of Excellence by National Cancer Institute and the Inspired Excellence in Health Care Award by Las Vegas HEALS.
Dr. Vogelzang has been featured in several national and local media outlets in relation to his cancer research work including The New York Times, USA Today, New England Journal of Medicine, Nature, 60 Minutes and the Las Vegas Review-Journal.
Dr. Vogelzang has served on numerous committees for the American Society of Clinical Oncology (ASCO), as well as on its board of directors for three years.
Primary Specialty
Oncologist
Gender
Male
Training
Rush Presbyterian St. Luke’s Medical Center, Rush Presbyterian St. Luke’s Medical Center, University of Minnesota
Certification
Internal Medicine, Medical Oncology
Services
Chemotherapy, Clinical Research, Immunotherapy
Consumer Feedback
Add a Review
There are no recent reviews. Be the first!
©2024 Wellness®.com is a registered trademark of Wellness.com, Inc. 